Live and recent posts from across the Fediverse tagged #chronicrhinosinusitis, aggregated by home.social.
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
Sanofi’s SNY Dupixent, which it co-develops with Regeneron REGN, is its key top-line driver. The drug has transformed the treatment…
#France #FR #Europe #EU #Sanofi #approvedindications #atopicdermatitis #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #inflammatorydiseases #Regeneron #severeasthma #ZacksInvestmentResearch
https://www.europesays.com/france/40120/
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth…
#France #FR #Europe #EU #Sanofi #approvedindications #blockbusterdrug #chronicrhinosinusitis #pneumococcalconjugatevaccine #rabiesvaccine #SNYstock #strongsales #ZacksInvestmentResearch
https://www.europesays.com/france/31768/
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth…
#France #FR #Europe #EU #Sanofi #approvedindications #blockbusterdrug #chronicrhinosinusitis #pneumococcalconjugatevaccine #rabiesvaccine #SNYstock #strongsales #ZacksInvestmentResearch
https://www.europesays.com/france/30767/
SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…
#NewsBeep #News #Medication #antihistamines #CA #Canada #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #EuropeanCommission #europeanunion #Health #inflammatorydiseases #Regeneron #Sanofi #severeasthma #ZacksInvestmentResearch
https://www.newsbeep.com/ca/307594/
https://www.europesays.com/uk/593972/ SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria #Antihistamines #ChronicRhinosinusitis #ChronicSpontaneousUrticaria #Dupixent #EuropeanCommission #EuropeanUnion #Health #InflammatoryDiseases #Medication #Regeneron #Sanofi #SevereAsthma #UK #UnitedKingdom #ZacksInvestmentResearch
https://www.europesays.com/ie/200303/ SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria #Antihistamines #ChronicRhinosinusitis #ChronicSpontaneousUrticaria #Dupixent #Éire #EuropeanCommission #EuropeanUnion #Health #IE #InflammatoryDiseases #Ireland #Medication #Regeneron #Sanofi #SevereAsthma #ZacksInvestmentResearch
SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #antihistamines #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #EuropeanCommission #EuropeanUnion #Health #inflammatorydiseases #Regeneron #Sanofi #severeasthma #ZacksInvestmentResearch
https://www.newsbeep.com/us/313749/
https://www.europesays.com/2539777/ A Fresh Look at Amgen (AMGN) Valuation After Key EU Drug Approval and Upcoming Clinical Data Releases #Amgen #ChronicRhinosinusitis #CompanyFundamentals #Data #PhaseIII #ProductLaunches #UntappedPotential